TRAF7
TRAF7 (TNF receptor associated factor 7, also known as RNF119 or RFWD1) is an E3 ubiquitin and SUMO-protein ligase. It contributes to innate immunity, inflammation and apoptosis, and it restrains NF-kappa-B and antiviral signalling. Browse Assay Genie's current range of TRAF7 research reagents below, or read on for the biology behind the target.
TRAF7 is an E3 ubiquitin and SUMO-protein ligase that acts in several biological processes, including innate immunity, inflammation and apoptosis. It potentiates MAP3K3-mediated activation of the JUN/AP1 and DDIT3 transcriptional regulators, and it contributes to the phosphorylation of MAPK1 and/or MAPK3, probably through its interaction with MAP3K3. Through SUMOylation, TRAF7 negatively regulates MYB transcriptional activity by sequestering MYB in the cytosol.
TRAF7 also acts as a brake on innate immune signalling. It negatively regulates RLR-mediated innate immunity by promoting 'Lys-48'-linked ubiquitination of TBK1 through its RING domain, which inhibits the cellular antiviral response. It promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA, targeting both proteins to lysosomal degradative pathways and reducing the transcriptional activity of NF-kappa-B. UniProt records the protein in the cytoplasmic vesicle, cytoplasm and nucleus.
TNF receptor-associated factors such as TRAF7 are signal transducers for members of the TNF receptor superfamily. TRAFs typically have an N-terminal cysteine/histidine-rich region with zinc RING and/or zinc finger motifs, a coiled-coil (leucine zipper) motif and a TRAF domain involved in self-association and receptor binding. TRAF7 belongs to the WD repeat TRAF7 family, and HGNC places the TRAF7 gene among the ring finger, WD repeat domain containing and TRAF-type zinc finger groups. Earlier names include ring finger and WD repeat domain 1 (RFWD1) and RNF119. The mouse ortholog is Traf7.
TRAF7 promotes Lys-48-linked ubiquitination of TBK1, inhibiting the RLR-mediated antiviral response, so it is studied as a negative regulator of innate immunity.
TRAF7 drives Lys-29-linked polyubiquitination of NEMO/IKBKG and RELA, sending them to lysosomal degradation and lowering NF-kappa-B transcriptional activity.
TRAF7 potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 and contributes to MAPK1 and MAPK3 phosphorylation.
As a dual E3 ubiquitin and SUMO ligase, TRAF7 SUMOylates MYB to hold it in the cytosol, linking post-translational modification to transcription control.
TRAF7 is an E3 ubiquitin and SUMO-protein ligase involved in innate immunity, inflammation and apoptosis. It ubiquitinates TBK1, NEMO/IKBKG and RELA to dampen antiviral and NF-kappa-B signalling, and it SUMOylates MYB to sequester it in the cytosol.
HGNC lists the aliases RNF119, RFWD1, DKFZp586I021 and MGC7807. Previous names include ring finger and WD repeat domain 1 and TNF receptor-associated factor 7, E3 ubiquitin protein ligase. UniProt calls the protein E3 ubiquitin-protein ligase TRAF7.
The mouse ortholog is Traf7. TRAF7 belongs to the TNF receptor associated factor group, alongside TRAF2, TRAF3, TRAF4, TRAF5 and TRAF6, but it is also a WD repeat protein. Check the datasheet of any product for its validated reactivity.
Other TNF receptor associated factors and E3 ligases involved in NF-kappa-B and innate immune signalling.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q6Q0C0; product specifications from Assay Genie datasheets.